Abstract
Gastric neuroendocrine carcinoma is a comparatively rare entity and accounts for 0,6% of all gastric malignancies. The classification, pathology, and treatment of the malignancy are still incompletely understood. Of a total of 2,094 cases operated on in our center from January 1994 to December 2011, eighteen cases of histopathological neuroendocrine neoplasms were reviewed. Based on the WHO classification in 2010, histopathological types of these eighteen cases were classified into neuroendocrine tumor G1 in one case, neuroendocrine tumor G2 in three cases, neuroendocrine adenocarcinoma in thirteen cases, and mixed adenoendocrine carcinoma in the remaining case. The prognosis of neuroendocrine carcinoma is poor. However, we consider that early operation can increases prolong the survival time. Even an unresectable patient survived for fifteen months by chemotherapy. Therefore we can expect the effectiveness of chemotherapy as well.
